An update on heart disease risk associated with testosterone boosting medications. Issue 4 (3rd April 2019)

• Record Type: Journal Article
• Authors: Corona, G; Rastrelli, G; Guaraldi, F; Tortorici, G; Reismann, Y; Sforza, A; Maggi, M
• Is Part Of: Expert opinion on drug safety. Volume 18:Issue 4(2019)
• Page Start: 321
• Page End: 332
• Publication Date: 2019-04-03
• Subjects: Testosterone -- cardiovascular diseases -- heart failure -- ischemic heart diseases; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2019.1607290
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : The cardiovascular (CV) safety of testosterone replacement therapy (TRT) remains a crucial issue in the management of subjects with late-onset hypogonadism. The authors systematically reviewed and discussed the available evidence focusing our analysis on heart-related issues. Areas covered : All the available data from prospective observational studies evaluating the role endogenous T levels on the risk of acute myocardial infarction (AMI) were collected and analyzed. In addition, the impact of TRT on heart-related diseases, as derived from pharmaco-epidemiological studies as well as from randomized placebo-controlled trials (RCTs), was also investigated. Expert opinion : Available evidence indicates that endogenous low T represents a risk factor of AMI incidence and its related mortality. TRT in hypogonadal patients is able to improve angina symptoms in subjects with ischemic heart diseases and exercise ability in patients with heart failure (HF). In addition, when prescribed according to the recommended dosage, TRT does not increase the risk of heart-related events.